Simon Delagrave, PhD
SVP of Platform and Biology
Simon joined Ring Therapeutics as head of Platform and Biology in August 2018. He is former head of virology research and interim head of research with Sanofi Pasteur North America, where he worked for 13 years. He led the development of ACAM529, a candidate vaccine against genital herpes that completed Phase 1 clinical testing. Simon participated in the development of the licensed vaccine Imojev against Japanese encephalitis, and recombinant antibodies against influenza and respiratory syncytial virus. In earlier work, he applied directed evolution to discover improved enzymes and the first useful variant of the green fluorescent protein. Simon obtained a BSc in biochemistry from McGill University and a PhD from MIT in biological chemistry.